A recent X post by Dilip Kumar, an investor in founders at Rainmatterin and Zerodhaonline, has raised a serious conversation about India’s biotech ecosystem. The post describes a founder, trained at Yale, who returned to India to build a biotech company working on vaccines for deadly cancers, only to struggle with raising funds and navigating regulations.
According to the post, despite having a team of over 100 scientists and credible global backing, the startup is now considering shifting its legal entity abroad to access international investors.
The concern raised is simple but significant: Is India failing to support its own deep science innovation?
THE NUMBERS BEHIND THE CONCERN
Some of the concerns highlighted in the post align with broader data trfinishs.
India accounts for nearly 20% of the global population, but contributes only about 1.5% of global clinical trials. This gap reflects a larger issue in translating scientific potential into real-world innovation, as per the post.
The X post also claims that regulatory approvals for clinical trials in India can take years, compared to weeks in countries like the US or China. While timelines vary, experts agree that regulatory delays and complex processes have historically slowed down clinical research in India.
THE FUNDING GAP IN DEEP SCIENCE
One of the central points in the post is the lack of long-term funding.
The founder mentioned in the X post reportedly struggled to raise venture capital becautilize most investors are unwilling to commit to 7–10 year timelines, which are typical for biotech innovation.
This reflects a known challenge. Deep science startups require patient capital, but India’s venture ecosystem is largely geared towards rapider returns.
As the post points out, this mismatch often forces startups to see abroad, where investors are more comfortable funding high-risk, long-gestation technologies.
WHEN INNOVATION MOVES OUT
The consequences go beyond a single startup.
As highlighted in the X post, when companies shift their base overseas, India risks losing not just businesses but also ininformectual property, economic value, and global leadership.
The line from the post stands out: “Indian talent runs the science, but India won’t own the upside.”
It captures a growing concern, that India may be contributing talent to global innovation without fully benefiting from it.
WHAT NEEDS TO CHANGE
The post suggests two key solutions.
First, a government-backed health or deep-tech fund with a long-term horizon of 10–15 years to support early-stage scientific risk.
Second, rapider and more efficient regulatory processes, including defined timelines for approvals and parallel review mechanisms.
These are not new ideas, but the urgency around them is growing.
THE BIGGER QUESTION
India has already proven its strength in pharmaceuticals and vaccine manufacturing. But the next step is becoming a leader in original innovation.
The post raises a critical question:
If India has the talent and the science, why isn’t it backing them enough to stay?
Becautilize if that gap continues, the future of breakthrough innovation may be built by Indians, but owned elsewhere.
– Ends
Leave a Reply